Seres Therapeutics annual loss widens

Patheon, Seres Therapeutics, Wynn Resorts Stocks Moving Today --> Patheon, Seres Therapeutics, Wynn Resorts Stocks Moving Today

Patheon, Seres Therapeutics, Wynn Resorts Stocks Moving Today --> Patheon, Seres Therapeutics, Wynn Resorts Stocks Moving Today

One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. Canaccord Genuity reiterated a "buy" rating and issued a $20.00 price target on shares of Seres Therapeutics in a research note on Tuesday, January 31st.

On Sep 16 Seres Therapeutics, Inc. The average 12-month price target among brokerages that have issued ratings on the stock in the previous year is $23.20. FBR & Co cut their target price on shares of Seres Therapeutics from $23.00 to $18.00 and set an "outperform" rating on the stock in a report on Wednesday, February 1st. The 52-week low of the share price is at $8.05. Cowen and Company reiterated a "buy" rating on shares of Seres Therapeutics in a report on Wednesday, February 1st. The stock surged to a 4-month high. The company has a 50 day moving average of $9.69 and a 200 day moving average of $10.73.

The stock has a high price target of $57 according to consensus of 17 analysts. The company saw 0.86 million shares trade hands over the course of the day.

Brazil meat-packing giants 'exported rotten beef'
Investigators said employees at the food-processing giants JBS and BRF paid federal inspectors to ignore problems with meat. A significant percentage of the meat processed by these companies is exported to many countries including European nations.

Some of the changes that Seres Therapeutics will be making in the new trial include measuring the infection using a mechanism that is more accurate.

When Seres, the first publicly held microbiome-focused company, had a major clinical trial failure last summer for its fecal transplant aiming to treat recurrent C. diff. infection, the company's stock fell dramatically Conversely, its shares skyrocketed March 16 after the company reported fourth-quarter revenue that topped estimates, filed for a mixed-shelf offering of up to $150 million, and revealed plans to initiate the new mid-stage study for SER-109. Fidelity Management and Research Company is the second biggest holder with 6 million shares now valued at 60.47 million whilst Federated Global Inv Mgmt Corp has 2 million shares valued at 25.12 million. The company had revenue of $3.00 million for the quarter, compared to analysts expectations of $3.00 million. ACI Worldwide, Inc. (NASDAQ:ACIW) quarterly performance is 24.48% while its year to date (YTD) performance is 25.51%.

A number of institutional investors have recently bought and sold shares of MCRB. Artal Group S.A. raised its stake in Seres Therapeutics by 40.0% in the fourth quarter. The consensus estimate for current quarter is $-0.7 and for the current fiscal year, the estimate is $-2.41. Renaissance Technologies LLC raised its stake in Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the company's stock worth $3,963,000 after buying an additional 103,800 shares in the last quarter. Finally, Trexquant Investment LP raised its stake in shares of Seres Therapeutics by 147.5% in the fourth quarter. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI. The increase in fourth quarter net loss was driven primarily by continued growth in clinical and development expenses as well as increased headcount, and ongoing development of the company's microbiome therapeutics platform.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.